This episode unpacks the 2025 landscape for the FDA's Breakthrough Devices Program and the transformative new CMS Transitional Coverage for Emerging Technologies (TCET) pathway. We explore how these initiatives are accelerating device clearance and Medicare coverage, including the impact of over 1,000 Breakthrough designations granted by September 2024 and TCET's August 2024 finalization. We delve into the benefits, eligibility, and current limitations, such as TCET's five-device annual cap and exclusion of diagnostics. Key Questions: • How is the FDA's Breakthrough Devices Program evolving in 2025 to speed up device approval? • What does the milestone of over 1,041 Breakthrough Device designations by September 2024 signify for MedTech innovators? • Can the Breakthrough program really cut medical device approval timelines in half? • What is the new CMS TCET pathway finalized in August 2024, and how does it link to FDA Breakthrough Devices? • How quickly does TCET aim to provide national Medicare coverage post-FDA authorization? • What are the specific criteria for a device to qualify for the TCET pathway? • Why are industry groups concerned about TCET's current annual device limit? • Are diagnostic technologies eligible for accelerated Medicare coverage under TCET in 2025? • What are the key differences between the FDA Breakthrough Pathway and the CMS TCET Pathway? • How can these 2025 regulatory updates impact your strategy for U.S. market access? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.